Trials / Conditions / Cutaneous Lupus Erythematosus

Cutaneous Lupus Erythematosus

23 registered clinical trials studyying Cutaneous Lupus Erythematosus — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease ( NCT07355218	EMD Serono Research & Development Institute, Inc.	Phase 3
Not Yet Recruiting	Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.. NCT07408908	Xiamen Amoytop Biotech Co., Ltd.	Phase 1
Recruiting	Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants NCT07072611	Noxopharm Limited	EARLY_Phase 1
Enrolling By Invitation	Tapinarof for Cutaneous Lupus Erythematosus NCT06661213	Northwestern University	EARLY_Phase 1
Recruiting	A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute NCT06015737	AstraZeneca	Phase 3
Recruiting	Deep Phenotyping of Cutaneous Lupus Erythematosus NCT06411106	Centre for Human Drug Research, Netherlands	N/A
Terminated	Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) NCT04809623	Gilead Sciences	Phase 1
Completed	Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus NCT04781816	Sanofi	Phase 2
Completed	Study of M5049 in CLE and SLE Participants NCT04647708	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	Phase 1
Completed	A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythemat NCT03817424	Amgen	Phase 1
Unknown	Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus NCT03260166	Second Xiangya Hospital of Central South University	Phase 2
Completed	Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Act NCT03134222	Gilead Sciences	Phase 2
Completed	IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus NCT01841619	University of California, Irvine	EARLY_Phase 1
Completed	Low-dose UVA1 Radiation in Cutaneous Lupus Patients NCT01776190	Ben Chong	N/A
Completed	Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus NCT01629784	Northwestern University	N/A
Terminated	Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus NCT01498406	Emory University	Phase 2
Terminated	A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus NCT01470313	Pfizer	Phase 1
Completed	To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 NCT01300208	Amgen	Phase 2
Completed	Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) NCT01146444	Spirig Pharma Ltd.	N/A
Completed	Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser NCT00523588	University of Pennsylvania	Phase 2
Completed	Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE) NCT00317681	Heinrich-Heine University, Duesseldorf	Phase 2
Completed	Interdisciplinary Study Group of Lupus Erythematosus (ISGLE) NCT00420173	European Society of Cutaneous Lupus Erythematosus e.V.	—
Completed	Sunscreen RV 2457C in Photoinduced CLE NCT00470912	Heinrich-Heine University, Duesseldorf	Phase 3